Effect of Rituximab on Neurofilament Levels in CIDP: Results From the CIDPRIT Randomized Trial

Area of Science:

• Neurology
• Immunology
• Biomarker Research

Background:

• Rituximab is a proposed treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but clinical evidence is limited.
• The CIDPRIT trial showed no overall clinical benefit of rituximab versus placebo.
• Serum neurofilament light chain (sNfL) may serve as a biomarker for rituximab's effects in CIDP.

Purpose of the Study:

• To investigate rituximab's effect on sNfL levels in CIDP patients.
• To explore the correlation between sNfL and clinical outcomes in the CIDPRIT trial.
• To assess sNfL as a potential biomarker for treatment response in CIDP.

Main Methods:

• Post hoc analysis of sNfL levels from the CIDPRIT trial.
• sNfL measurement using Simoa technology at baseline, 6, and 12 months.
• Statistical analysis including linear mixed-effects models and survival analyses.

Main Results:

• 33 participants (18 rituximab, 15 placebo) were analyzed.
• Baseline sNfL was higher in the rituximab group (p=0.019).
• Rituximab patients showed stable/decreased sNfL over 12 months, unlike placebo. sNfL correlated with axonal damage parameters.

Conclusions:

• Biomarker analysis did not confirm rituximab efficacy in CIDP.
• Observed sNfL trends suggest a potential biological effect on axonal injury in a subset of patients.
• Further research is needed to validate sNfL for treatment monitoring and patient stratification in CIDP.